Display options
Cite
Perez DR, Sklar LA, Chigaev A, et al. Drug repurposing for targeting cyclic nucleotide transporters in acute leukemias - A missed opportunity. Semin Cancer Biol. 2020;68:199-208doi: 10.1016/j.semcancer.2020.02.004.
Perez, D. R., Sklar, L. A., Chigaev, A., & Matlawska-Wasowska, K. (2021). Drug repurposing for targeting cyclic nucleotide transporters in acute leukemias - A missed opportunity. Seminars in cancer biology, 68199-208. https://doi.org/10.1016/j.semcancer.2020.02.004
Perez, Dominique R, et al. "Drug repurposing for targeting cyclic nucleotide transporters in acute leukemias - A missed opportunity." Seminars in cancer biology vol. 68 (2021): 199-208. doi: https://doi.org/10.1016/j.semcancer.2020.02.004
Perez DR, Sklar LA, Chigaev A, Matlawska-Wasowska K. Drug repurposing for targeting cyclic nucleotide transporters in acute leukemias - A missed opportunity. Semin Cancer Biol. 2021 Jan;68:199-208. doi: 10.1016/j.semcancer.2020.02.004. Epub 2020 Feb 07. PMID: 32044470; PMCID: PMC7415530.
Copy Download .nbib Format: NLM
Share it on

Semin Cancer Biol. 2021 Jan;68:199-208. doi: 10.1016/j.semcancer.2020.02.004. Epub 2020 Feb 07.

Drug repurposing for targeting cyclic nucleotide transporters in acute leukemias - A missed opportunity.

Seminars in cancer biology

Dominique R Perez, Larry A Sklar, Alexandre Chigaev, Ksenia Matlawska-Wasowska

Affiliations

  1. Department of Pathology, Health Sciences Center, University of New Mexico, Albuquerque, NM, USA; Center for Molecular Discovery, Health Sciences Center, University of New Mexico, Albuquerque, NM, USA.
  2. Department of Pathology, Health Sciences Center, University of New Mexico, Albuquerque, NM, USA; Center for Molecular Discovery, Health Sciences Center, University of New Mexico, Albuquerque, NM, USA; University of New Mexico Comprehensive Cancer Center, Albuquerque, NM, USA.
  3. Department of Pathology, Health Sciences Center, University of New Mexico, Albuquerque, NM, USA; Center for Molecular Discovery, Health Sciences Center, University of New Mexico, Albuquerque, NM, USA; University of New Mexico Comprehensive Cancer Center, Albuquerque, NM, USA. Electronic address: [email protected].
  4. University of New Mexico Comprehensive Cancer Center, Albuquerque, NM, USA; Department of Pediatrics, Division of Hematology-Oncology, Health Sciences Center, University of New Mexico, Albuquerque, NM, USA. Electronic address: [email protected].

PMID: 32044470 PMCID: PMC7415530 DOI: 10.1016/j.semcancer.2020.02.004

Abstract

While current treatment regimens for acute leukemia can dramatically improve patient survival, there remains room for improvement. Due to its roles in cell differentiation, cell survival, and apoptotic signaling, modulation of the cyclic AMP (cAMP) pathway has provided a meaningful target in hematological malignancies. Several studies have demonstrated that gene expression profiles associated with increased pro-survival cAMP activity or downregulation of various pro-apoptotic factors associated with the cAMP pathway are apparent in acute leukemia patients. Previous work to increase leukemia cell intracellular cAMP focused on the use of cAMP analogs, stimulating cAMP production via transmembrane-associated adenylyl cyclases, or decreasing cAMP degradation by inhibiting phosphodiesterase activity. However, targeting cyclic nucleotide efflux by ATP-binding cassette (ABC) transporters represents an unexplored approach for modulation of intracellular cyclic nucleotide levels. Preliminary studies have shown that inhibition of cAMP efflux can stimulate leukemia cell differentiation, cell growth arrest, and apoptosis, indicating that targeting cAMP efflux may show promise for future therapeutic development. Furthermore, inhibition of cyclic nucleotide transporter activity may also contribute multiple anticancer benefits by reducing extracellular pro-survival signaling in malignant cells. Hence, several opportunities for drug repurposing may exist for targeting cyclic nucleotide transporters.

Copyright © 2020 Elsevier Ltd. All rights reserved.

Keywords: 3',5'-cyclic adenosine monophosphate (cAMP); ATP-binding cassette (ABC) transporters; Acute lymphoblastic leukemia (ALL); Acute myelogenous leukemia (AML); Efflux; Inhibitors of cAMP efflux (ICE)

References

  1. Proc Natl Acad Sci U S A. 2008 Dec 9;105(49):19532-7 - PubMed
  2. J Biol Chem. 2012 Dec 21;287(52):43789-97 - PubMed
  3. J Cell Physiol. 1999 Jul;180(1):71-80 - PubMed
  4. Life Sci. 2015 Jan 15;121:166-73 - PubMed
  5. Mol Cancer. 2011 Apr 21;10:45 - PubMed
  6. Lancet Oncol. 2010 May;11(5):429-38 - PubMed
  7. Pharmacol Ther. 2000 Aug-Sep;87(2-3):199-226 - PubMed
  8. Oncotarget. 2015 May 20;6(14):12048-60 - PubMed
  9. Vet Comp Oncol. 2017 Dec;15(4):1585-1589 - PubMed
  10. Methods Mol Biol. 2016;1439:227-44 - PubMed
  11. Front Pharmacol. 2015 Jul 02;6:134 - PubMed
  12. Acta Physiol (Oxf). 2012 Feb;204(2):277-87 - PubMed
  13. Elife. 2018 Jan 16;7: - PubMed
  14. J Biol Chem. 2011 Mar 4;286(9):6979-88 - PubMed
  15. Blood. 2008 Feb 1;111(3):1182-92 - PubMed
  16. Adv Cancer Res. 2015;125:171-96 - PubMed
  17. Curr Top Med Chem. 2016;16(13):1441-51 - PubMed
  18. J Cell Biol. 1999 May 31;145(5):951-9 - PubMed
  19. Oncotarget. 2015 Jun 20;6(17):14970-81 - PubMed
  20. Medchemcomm. 2018 Jul 11;9(8):1249-1272 - PubMed
  21. Nat Rev Clin Oncol. 2015 Jun;12(6):344-57 - PubMed
  22. Nat Cell Biol. 2007 Apr;9(4):415-21 - PubMed
  23. Int J Mol Cell Med. 2016 Fall;5(4):220-228 - PubMed
  24. Best Pract Res Clin Haematol. 2011 Dec;24(4):489-503 - PubMed
  25. J Clin Oncol. 2013 Dec 10;31(35):4407-15 - PubMed
  26. Cytometry B Clin Cytom. 2012 Sep;82(5):283-94 - PubMed
  27. J Pediatr Hematol Oncol. 2014 Jan;36(1):8-15 - PubMed
  28. Cancer Cell. 2005 Apr;7(4):351-62 - PubMed
  29. Science. 2000 Jul 28;289(5479):625-8 - PubMed
  30. Blood. 2011 Dec 1;118(23):6141-52 - PubMed
  31. Pediatr Int. 2015 Dec;57(6):1059-66 - PubMed
  32. Cancer Discov. 2012 Sep;2(9):840-55 - PubMed
  33. Eur J Pharmacol. 2017 Jan 5;794:201-208 - PubMed
  34. J Immunol. 2009 May 1;182(9):5400-11 - PubMed
  35. Neoplasia. 2011 Jul;13(7):653-63 - PubMed
  36. Blood Cancer J. 2016 Jul 01;6(7):e441 - PubMed
  37. Curr Opin Pharmacol. 2016 Aug;29:7-16 - PubMed
  38. Pflugers Arch. 2013 Oct;465(10):1397-407 - PubMed
  39. Annu Rev Genomics Hum Genet. 2002;3:179-98 - PubMed
  40. Int J Biochem Cell Biol. 2014 Mar;48:92-6 - PubMed
  41. EMBO J. 2001 Apr 17;20(8):1921-30 - PubMed
  42. Int J Cancer. 2009 May 15;124(10):2303-11 - PubMed
  43. Leuk Lymphoma. 2000 Mar;37(1-2):39-51 - PubMed
  44. Biochem Pharmacol. 2012 Apr 15;83(8):1073-83 - PubMed
  45. Int J Cancer. 2005 Jun 20;115(3):499-501 - PubMed
  46. BMC Immunol. 2011 May 17;12:28 - PubMed
  47. Leukemia. 2015 Feb;29(2):312-20 - PubMed
  48. J Biol Chem. 2016 Jul 8;291(28):14483-98 - PubMed
  49. Curr Opin Cell Biol. 2015 Apr;33:42-8 - PubMed
  50. Nat Commun. 2015 Mar 19;6:6604 - PubMed
  51. Clin Cancer Res. 1999 Jul;5(7):1682-9 - PubMed
  52. Mol Biol Cell. 2012 May;23(9):1618-27 - PubMed
  53. Cancer Res. 2017 Jan 15;77(2):390-400 - PubMed
  54. Leukemia. 2016 Dec;30(12):2302-2311 - PubMed
  55. Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1547-52 - PubMed
  56. J Biol Chem. 2011 Sep 23;286(38):33260-7 - PubMed
  57. Kidney Int. 2011 Jun;79(12):1277-88 - PubMed
  58. J Clin Med. 2015 Apr;4(4):665-95 - PubMed
  59. J Biol Chem. 1980 Mar 10;255(5):1771-4 - PubMed
  60. J Cancer Res Clin Oncol. 2008 Mar;134(3):365-72 - PubMed
  61. FASEB J. 2003 Jan;17(1):82-4 - PubMed
  62. Biochim Biophys Acta Bioenerg. 2018 Sep;1859(9):868-877 - PubMed
  63. Mol Cell Biol. 1996 Feb;16(2):694-703 - PubMed
  64. Cell Metab. 2013 Oct 1;18(4):578-87 - PubMed
  65. Biochim Biophys Acta. 2014 Dec;1842(12 Pt B):2646-55 - PubMed
  66. Proc Natl Acad Sci U S A. 2013 Sep 3;110(36):14711-6 - PubMed
  67. Cancer. 2010 Jun 1;116(11):2507 - PubMed
  68. Steroids. 2001 Jan;66(1):39-47 - PubMed
  69. J Biol Chem. 1963 Sep;238:3009-15 - PubMed
  70. Leukemia. 2004 Oct;18(10):1605-10 - PubMed
  71. J Immunol. 1995 Feb 15;154(4):1634-43 - PubMed
  72. Front Pharmacol. 2015 Mar 24;6:58 - PubMed
  73. Cancer Cell. 2016 Sep 12;30(3):391-403 - PubMed
  74. J Clin Oncol. 2008 Jun 20;26(18):3038-45 - PubMed
  75. Cancers (Basel). 2014 Feb 26;6(1):436-58 - PubMed
  76. N Engl J Med. 2015 Oct 15;373(16):1541-52 - PubMed
  77. Neoplasia. 2011 Mar;13(3):206-16 - PubMed
  78. Cardiovasc Res. 2008 Jul 15;79(2):208-17 - PubMed
  79. N Engl J Med. 2013 May 30;368(22):2059-74 - PubMed
  80. Clin Pharmacol Ther. 2012 Nov;92(5):545-6 - PubMed
  81. Trends Endocrinol Metab. 2012 Sep;23(9):459-66 - PubMed
  82. Cell Metab. 2009 Mar;9(3):265-76 - PubMed
  83. J Immunol. 2008 Jul 1;181(1):464-75 - PubMed
  84. J Biol Chem. 2000 May 5;275(18):13662-7 - PubMed
  85. J Leukoc Biol. 2014 Jul;96(1):113-22 - PubMed
  86. Clin Cancer Res. 1997 Oct;3(10):1781-7 - PubMed
  87. Br J Haematol. 2000 Mar;108(3):565-73 - PubMed
  88. Cancer Immunol Immunother. 2011 Oct;60(10):1405-18 - PubMed
  89. Pharmacol Ther. 2014 Sep;143(3):295-304 - PubMed
  90. Cell Death Dis. 2011 Dec 08;2:e237 - PubMed
  91. Biochim Biophys Acta. 2014 Dec;1842(12 Pt B):2535-47 - PubMed
  92. J Biol Chem. 1958 Jun;232(2):1065-76 - PubMed
  93. Mol Pharmacol. 2011 Aug;80(2):281-93 - PubMed
  94. Physiology (Bethesda). 2007 Oct;22:320-7 - PubMed
  95. J Biol Chem. 2004 May 14;279(20):20858-65 - PubMed
  96. Blood. 2002 Apr 1;99(7):2617-9 - PubMed
  97. Oncotarget. 2016 Dec 27;7(52):87232-87245 - PubMed
  98. JAMA. 1999 Oct 6;282(13):1254-7 - PubMed
  99. Cell Physiol Biochem. 2018;45(6):2516-2528 - PubMed
  100. Cardiovasc Res. 2013 Sep 1;99(4):734-42 - PubMed
  101. Cell. 2011 Jan 21;144(2):227-39 - PubMed
  102. Biochim Biophys Acta. 2014 Dec;1842(12 Pt B):2636-45 - PubMed
  103. BMC Immunol. 2008 Jun 05;9:26 - PubMed
  104. Cancer Biol Med. 2016 Mar;13(1):41-54 - PubMed
  105. Oncol Lett. 2012 Dec;4(6):1384-1388 - PubMed
  106. Blood. 1991 Jul 15;78(2):488-92 - PubMed
  107. Nature. 1976 Jan 29;259(5541):321-3 - PubMed
  108. J Cell Biol. 2004 Feb 16;164(4):527-34 - PubMed
  109. Biochem J. 2002 Feb 1;361(Pt 3):497-503 - PubMed
  110. J Biol Chem. 2010 Dec 31;285(53):41222-31 - PubMed
  111. Biochim Biophys Acta. 2007 Sep;1770(9):1352-9 - PubMed
  112. Cell Rep. 2017 Jan 10;18(2):468-481 - PubMed
  113. Comput Struct Biotechnol J. 2015 Apr 08;13:265-72 - PubMed
  114. Am J Pathol. 1975 Oct;81(1):199-204 - PubMed
  115. Hum Immunol. 2008 Dec;69(12):833-6 - PubMed
  116. Handb Exp Pharmacol. 2017;241:141-160 - PubMed
  117. Clin Cancer Res. 2009 Mar 1;15(5):1762-9 - PubMed
  118. Aging (Albany NY). 2016 Nov 19;8(11):2936-2947 - PubMed
  119. Expert Opin Ther Targets. 2013 Aug;17(8):937-49 - PubMed
  120. Leukemia. 2011 Aug;25(8):1374-6 - PubMed
  121. J Transl Med. 2007 May 04;5:23 - PubMed
  122. Biochem Biophys Res Commun. 2015 Sep 11;465(1):47-52 - PubMed
  123. Oncotarget. 2016 Jun 7;7(23):33960-82 - PubMed
  124. Semin Hematol. 2014 Oct;51(4):282-97 - PubMed
  125. Sci Rep. 2017 May 22;7(1):2243 - PubMed
  126. Cell Mol Life Sci. 2016 Dec;73(24):4577-4590 - PubMed
  127. Mol Cell Endocrinol. 2012 Apr 28;353(1-2):3-9 - PubMed
  128. Biochem Biophys Res Commun. 2004 Feb 13;314(3):798-804 - PubMed
  129. Cancer Res. 2010 Mar 15;70(6):2245-55 - PubMed
  130. EXCLI J. 2014 Aug 18;13:843-55 - PubMed
  131. Blood. 2012 Feb 23;119(8):1872-81 - PubMed
  132. J Cell Sci. 1999 Aug;112 ( Pt 16):2725-36 - PubMed
  133. Haematologica. 2014 Mar;99(3):430-6 - PubMed
  134. J Clin Endocrinol Metab. 1997 Dec;82(12):4044-8 - PubMed
  135. Cell Death Dis. 2013 Feb 28;4:e516 - PubMed
  136. Cancer Res. 2018 Apr 1;78(7):1779-1791 - PubMed
  137. Cell Metab. 2014 Mar 4;19(3):357-72 - PubMed
  138. Apoptosis. 2014 Jul;19(7):1069-79 - PubMed
  139. Cancer Res. 1998 Jul 1;58(13):2741-7 - PubMed
  140. Am J Physiol Cell Physiol. 2000 Nov;279(5):C1665-74 - PubMed
  141. Leukemia. 2016 Sep;30(9):1909-12 - PubMed
  142. Microvasc Res. 2006 Jul-Sep;72(1-2):48-53 - PubMed
  143. Microbes Infect. 2003 May;5(6):515-26 - PubMed
  144. J Cell Sci. 1998 Mar;111 ( Pt 5):637-44 - PubMed
  145. Annu Rev Pharmacol Toxicol. 2013;53:231-53 - PubMed
  146. Oncogene. 2013 Apr 4;32(14):1743-51 - PubMed
  147. Leukemia. 2008 Mar;22(3):665-7 - PubMed
  148. J Biol Chem. 2009 May 29;284(22):14760-8 - PubMed
  149. Lancet Oncol. 2013 Mar;14(3):199-209 - PubMed
  150. Cancer. 2005 Nov 1;104(9):1819-24 - PubMed
  151. Pharmacogenomics. 2012 Aug;13(11):1257-69 - PubMed
  152. Oncotarget. 2014 Oct 15;5(19):9308-21 - PubMed
  153. Clin Pharmacokinet. 2007;46(6):449-70 - PubMed
  154. Leukemia. 2008 Dec;22(12):2217-25 - PubMed
  155. Crit Rev Oncog. 2011;16(1-2):37-46 - PubMed
  156. J Biol Chem. 1990 Jul 5;265(19):10974-80 - PubMed
  157. IUBMB Life. 2009 Apr;61(4):394-406 - PubMed
  158. Blood. 2015 Jun 25;125(26):3977-87 - PubMed

Publication Types

Grant support